SONNET BIOTHERAPEUTICS HOLDI (SONN) Stock Fundamental Analysis

NASDAQ:SONN • US83548R4020

1.26 USD
-1.84 (-59.35%)
At close: Dec 2, 2025
1 USD
-0.26 (-20.63%)
After Hours: 12/2/2025, 8:07:49 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

0

SONN gets a fundamental rating of 0 out of 10. The analysis compared the fundamentals against 523 industry peers in the Biotechnology industry. SONN has a bad profitability rating. Also its financial health evaluation is rather negative. SONN does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year SONN has reported negative net income.
  • In the past year SONN has reported a negative cash flow from operations.
  • SONN had negative earnings in each of the past 5 years.
  • In the past 5 years SONN always reported negative operating cash flow.
SONN Yearly Net Income VS EBIT VS OCF VS FCFSONN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

  • With a Return On Assets value of -659.57%, SONN is not doing good in the industry: 97.18% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -659.57%
ROE N/A
ROIC N/A
ROA(3y)-375.01%
ROA(5y)-253.56%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SONN Yearly ROA, ROE, ROICSONN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5K 10K 15K

1.3 Margins

  • SONN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SONN Yearly Profit, Operating, Gross MarginsSONN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20K -40K -60K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. Health

2.1 Basic Checks

  • SONN does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for SONN has been increased compared to 1 year ago.
  • The number of shares outstanding for SONN has been increased compared to 5 years ago.
  • There is no outstanding debt for SONN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
SONN Yearly Shares OutstandingSONN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 200K 400K 600K
SONN Yearly Total Debt VS Total AssetsSONN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

  • Based on the Altman-Z score of -110.51, we must say that SONN is in the distress zone and has some risk of bankruptcy.
  • With a Altman-Z score value of -110.51, SONN is not doing good in the industry: 96.05% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -110.51
ROIC/WACCN/A
WACC8.83%
SONN Yearly LT Debt VS Equity VS FCFSONN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M -20M

2.3 Liquidity

  • A Current Ratio of 0.26 indicates that SONN may have some problems paying its short term obligations.
  • With a Current ratio value of 0.26, SONN is not doing good in the industry: 94.54% of the companies in the same industry are doing better.
  • A Quick Ratio of 0.26 indicates that SONN may have some problems paying its short term obligations.
  • With a Quick ratio value of 0.26, SONN is not doing good in the industry: 94.35% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.26
Quick Ratio 0.26
SONN Yearly Current Assets VS Current LiabilitesSONN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • SONN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 70.17%, which is quite impressive.
  • Looking at the last year, SONN shows a very strong growth in Revenue. The Revenue has grown by 1688.91%.
  • The Revenue for SONN have been decreasing by -77.28% on average. This is quite bad
EPS 1Y (TTM)70.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%83.04%
Revenue 1Y (TTM)1688.91%
Revenue growth 3Y-66.16%
Revenue growth 5Y-77.28%
Sales Q2Q%N/A

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y68.91%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SONN Yearly Revenue VS EstimatesSONN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2028 2029 2030 2031 20M 40M 60M 80M
SONN Yearly EPS VS EstimatesSONN Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2018 2020 2021 2022 2023 2024 2025 -500 -1K -1.5K -2K -2.5K

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for SONN. In the last year negative earnings were reported.
  • Also next year SONN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SONN Price Earnings VS Forward Price EarningsSONN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SONN Per share dataSONN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • SONN does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

SONNET BIOTHERAPEUTICS HOLDI

NASDAQ:SONN (12/2/2025, 8:07:49 PM)

After market: 1 -0.26 (-20.63%)

1.26

-1.84 (-59.35%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-13
Earnings (Next)12-15
Inst Owners9.95%
Inst Owner Change-0.31%
Ins Owners0.22%
Ins Owner Change-40.92%
Market Cap8.92M
Revenue(TTM)1.00M
Net Income(TTM)-13.56M
Analysts82.86
Price Target20.4 (1519.05%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-42.46%
Min EPS beat(2)-90.08%
Max EPS beat(2)5.16%
EPS beat(4)2
Avg EPS beat(4)-15.74%
Min EPS beat(4)-90.08%
Max EPS beat(4)31.98%
EPS beat(8)5
Avg EPS beat(8)1.79%
EPS beat(12)8
Avg EPS beat(12)10.51%
EPS beat(16)11
Avg EPS beat(16)11.95%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 8.92
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-7.23
EYN/A
EPS(NY)-3.53
Fwd EYN/A
FCF(TTM)-1.46
FCFYN/A
OCF(TTM)-1.46
OCFYN/A
SpS0.14
BVpS-0.43
TBVpS-0.43
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -659.57%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-375.01%
ROA(5y)-253.56%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.49
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 14.78%
Cap/Sales 1.2%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.26
Quick Ratio 0.26
Altman-Z -110.51
F-Score4
WACC8.83%
ROIC/WACCN/A
Cap/Depr(3y)4176.73%
Cap/Depr(5y)2511.15%
Cap/Sales(3y)207.2%
Cap/Sales(5y)124.63%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)70.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%83.04%
EPS Next Y68.91%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)1688.91%
Revenue growth 3Y-66.16%
Revenue growth 5Y-77.28%
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-14.52%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-468%
EBIT Next 3Y-90.14%
EBIT Next 5Y-41.82%
FCF growth 1Y55.58%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y55.05%
OCF growth 3YN/A
OCF growth 5YN/A

SONNET BIOTHERAPEUTICS HOLDI / SONN FAQ

Can you provide the ChartMill fundamental rating for SONNET BIOTHERAPEUTICS HOLDI?

ChartMill assigns a fundamental rating of 0 / 10 to SONN.


What is the valuation status of SONNET BIOTHERAPEUTICS HOLDI (SONN) stock?

ChartMill assigns a valuation rating of 0 / 10 to SONNET BIOTHERAPEUTICS HOLDI (SONN). This can be considered as Overvalued.


What is the profitability of SONN stock?

SONNET BIOTHERAPEUTICS HOLDI (SONN) has a profitability rating of 0 / 10.


Can you provide the expected EPS growth for SONN stock?

The Earnings per Share (EPS) of SONNET BIOTHERAPEUTICS HOLDI (SONN) is expected to grow by 68.91% in the next year.